PCG
FOLD

Private Capital Group’s Amicus Therapeutics FOLD Stock Holding History

Private Capital Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,774
Closed -$18K – 2136
2021
Q1 		$18K Hold
1,774
– – ﹤0.01% 1105
2020
Q4 		$41K Buy
1,774
+179
+11% +$3.66K 0.01% 886
2020
Q3 		$23K Buy
+1,595
New +$23.2K ﹤0.01% 1036

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Private Capital Group's FOLD Position: Q2 2021 in Review

Private Capital Group sold out of Amicus Therapeutics (FOLD) in Q2 2021, closing a stake of 1,774 shares — an estimated $18K sold.

Private Capital Group first reported a position in FOLD in Q3 2020 and held it in 3 quarters. The position peaked at $41K in Q4 2020. 235 funds tracked by Wall St. Rank hold FOLD as of Q2 2021.

  • Private Capital Group reported no remaining Amicus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Private Capital Group sold 1,774 Amicus Therapeutics shares in Q2 2021, an estimated $18K.
  • Private Capital Group first reported a position in Amicus Therapeutics in Q3 2020 and held it in 3 quarters.
  • Private Capital Group's Amicus Therapeutics position peaked at $41K in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2021.

Based on Private Capital Group's 13F filing for Q2 2021, filed 26 Jul 2021.